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Introduction 
Members of the genus Mycobacterium are wide- 
spread in nature, ranging from harmless inhabitants 
of water and soil to the agents of such devastating 
diseases as tuberculosis and leprosy. Tuberculosis is 
caused by M. tuberculosis, M. africanurn or M. bovis 
(1). These mycobacteria, together with M microti 
and 2M. bovis BCG, belong to the so-called M. 
tuberculosis complex. Tuberculosis still poses a major 
health problem in many parts of the world. The 
disease is responsible for over one-quarter of avoid- 
able deaths from infectious diseases (2). Mortality is 
highest in developing countries, where over three- 
quarters of cases occur (3). The problem is com- 
pounded by the emergence of M. tuberculosis strains 
which are resistant to drugs currently used (4-7). 
The human immunodeficiency virus (HIV) epi- 
demic is having a profound impact on the tubercu- 
losis problem in both industrialized and developing 
countries (6-9). The World Health Organization 
WHO) estimated that more than 8 million cases of 
tuberculosis occur each year with 3 million deaths, 
of which an increasing number are attributable to 
co-infection with HIV (estimated in 1995 to be 8.9%) 
(10). In Europe, HIV infection appears to contribute 
only marginally to the overall tuberculosis morbidity, 
except in large cities in southern Europe (11). Immi- 
gration from areas with a high prevalence of tuber- 
culosis appears to be a major contributor to the rising 
numbers of tuberculosis patients in Europe (11,12). 
Serious diseases caused by mycobacteria other 
than M tuberculosis, mostly mycobacteria belonging 
to the M avium-intracellulare (MAI) complex, have 
become very common in association with severe 
immunosuppression (13-16). This is not the situation 
in developing countries with a high incidence of 
tuberculosis, where disease due to mycobacteria 
other than M tuberculosis is rare (17,18). 
The increase in mycobacterial diseases has stimu- 
lated the development of more rapid and efficient 
methods of diagnosis. This review highlights some of 
the laboratory tests currently in use or under devel- 
opment for detection and identification of mycobac- 
teria. These tests range from simple staining methods 
to complex molecular biological techniques. 
Tests for Detection and Identification of 
Mycobacteria 
Two routes are used to attack the problem of 
diagnosis of tuberculosis or other mycobacterial dis- 
eases. The direct approach is concerned with the 
detection of the bacteria by microscopy or culture, 
detection of tuberculostearic acid, the identifi- 
cation of mycobacterial species by biochemical 
assays, detection and identification of mycobacterial 
antigens by the use of polyclonal or monoclonal 
antibodies, analysis of lipid compositions by 
chromatographic procedures and the detection of 
DNA or RNA of mycobacterial origin via hybridiz- 
ation with a DNA probe with or without amplifi- 
cation of nucleic acids. The indirect approach 
includes measurements of host immunity against the 
bacteria: humoral immunity via the detection of 
antibodies against the bacteria and cellular immunity 
via skin tests. 
DIRECT TESTS 
Microscopy 
Microscopy using a Ziehl-Neelsen or Kinyoun 
staining procedure or the fluorochrome procedure 
with such stains as auramine and rhodamine is rapid, 
cheap and easy. The limit of detection is 5000-10 000 
bacteria ml - ‘. The sensitivity varies depending on 
the source of the sample and the mycobacterium 
involved. Best results are obtained with respiratory 
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samples yielding M tuberculosis. Sensitivities range 
between 4678% and the specificity is virtually 100% 
(19-21). A common practice in well-equipped lab- 
oratories is to concentrate the clinical samples by 
centrifugation. This step improves the sensitivity of 
microscopy considerably (22). The use of cytocentri- 
fugation for the concentration of sputum samples has 
been reported by Saceanu et al., who found the 
sensitivity of microscopy increased dramatically from 
51% to almost 100% (23). 
Microscopy cannot identify the mycobacterial 
species. It is recommended that the result of 
microscopy should be confirmed by culture and 
identification when there is a chance that infection is 
due to mycobacteria other than M tuberculosis or 
when drug-sensitivity testing is required. 
Tuberculostearic acid 
An alternative to microscopy is the detection of 
tuberculostearic acid (TBSA) in clinical samples. 
TBSA is a cell wall fatty acid of mycobacteria 
and other actinomycetales, such as nocardia and 
actinomyces, and can be detected with gas 
chromatography-mass spectrometry combined with 
selective ion monitoring (24). Several authors have 
reported excellent results using this specialized tech- 
nique (25-27). The detection of TBSA in cerebro- 
spinal fluid (CSF) samples is one of the best 
approaches to the rapid diagnosis of tuberculous 
meningitis, but is impractical for the average routine 
laboratory because of the equipment and skill needed 
for the test. 
Antigen detection 
Enzyme-linked immunosorbent assays (ELISAs) 
using double-antibody sandwich procedures have 
been used for the detection of mycobacterial antigens 
in sputum (28), CSF (29-31) and pleural and ascites 
fluids (31). These tests lack specificity because poly- 
clonal antibodies are used. Rattan et al. used mono- 
clonal antibodies for detection of M. tuberculosis 
antigens in serum (32). 
Agglutination with sheep red blood cells sensitized 
with a monoclonal antibody directed against lipoara- 
binomannan (LAM) was used to detect antigens in 
patients with tuberculous meningitis (33). The test 
was positive in 22 of 25 patients with a positive 
culture. However, some false-positives were found in 
a few cases in the control group with pyogenic 
meningitis. Sada et al. developed an assay using 
Staphylococcus aweus bound with rabbit anti- 
bodies against LAM (34). The test was positive in 
44 of 50 sera from patients with microscopy- and 
culture-proven active pulmonary tuberculosis. No 
false-positives were found in control patients with 
lung disease other than tuberculosis. 
An agglutination assay using passive sensitization 
of latex particles with purified rabbit anti-M. tuber- 
culosis components has been used for the detection of 
M tuberculosis antigens in CSF from children with 
tuberculous meningitis (35). Cambiaso et al. used 
F(ab’), fragments against A4. bovis BCG for bind- 
ing to the latex beads, and an optical system which 
discriminates the unagglutinated from the aggluti- 
nated particles (36). These results were promising. 
None of the ELISAs or agglutination assays have 
been used on a large scale and their clinical use has 
yet to be proven. 
Culture 
The choice and preparation of specimens is impor- 
tant for culture. In pulmonary tuberculosis, sputum 
is the ideal specimen. Early morning sputum should 
be collected on three successive days. Induced 
sputum or bronchial washings are better than gastric 
washings or laryngeal swabs, as these are less 
reliable and may yield mycobacteria of little sig- 
nificance because they may reflect contaminating 
environmental mycobacteria. 
Isolation of mycobacteria from sputum is based on 
the relative resistance of these organisms to chemicals 
(e.g. sodium hydroxide, oxalic acid, sulphuric 
acid, various detergents). When treated with these 
chemicals, viscous sputum is homogenized and the 
numbers of unwanted fungi and bacteria are reduced 
while most of the mycobacteria survive. These effects 
are relative. Some contamination (about 3%) is advis- 
able since if contamination is absent, it is likely that 
the material has been over-decontaminated with loss 
of mycobacteria so that one may miss the diagnosis 
of paucibacillary tuberculosis. Decontamination is 
unnecessary for CSF and other material collected 
aseptically which can be inoculated directly on the 
media. 
The recommended practice is to culture on 
both solid and liquid media (37,38). Solid media 
include egg-based media such as Lowenstein-Jensen, 
Coletsos or agar-based media such as Middlebrook 
7HlO. Liquid media include Kirchner or 
Middlebrook 7H9 broth. However, most laboratories 
(about 70%) used solid media only for culture of 
mycobacteria (39,40). 
The isolation of mycobacteria by culture is 
hampered by their slow growth. A mean incubation 
of 4 weeks on conventional media is required before 
growth can be detected. There are three more 
rapid methods: the radiometric Bactec method, 
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Septi-Chek AFB and microcolony detection on solid 
media. 
The Bactec 460 radiometric (Becton Dickinson 
Instrument Systems, Sparks, MD, U.S.A.) system is 
an automated method for detecting i4C0, liberated 
by bacteria during metabolism and decarboxylation 
of i4C-labelled substrates. For detection of mycobac- 
teria, the system uses 14C-labelled palmitic acid as the 
substrate in modified Middlebrook 7H12 broth (41). 
Mycobacteria in clinical samples can be detected 
in half the time needed for conventional culture 
methods on solid media (42,43). With the Bactec 
system, the number of positive cultures may (4345) 
or may not be (46,47) higher than conventional 
culture on solid media. The Bactec system requires 
capital expenditure and the disposal of radioactive 
waste precludes its use in many laboratories. 
The Septi-Chek AFB system (Becton Dickinson 
Microbiology systems, Cockeysville, MD, U.S.A.) 
consists of a liquid phase Middlebrook 7H9 broth 
plus three solid media, Middlebrook 7Hll agar, 
modified egg medium and chocolate agar. Although 
the biphasic system requires more time (about 3 
weeks) than the Bactec system (about 2 weeks), it is 
comparable in terms of overall recovery (48). This 
method is cheaper than Bactec but more expensive 
than if one prepares the culture media oneself. 
A novel approach for isolation of mycobacteria 
from clinical specimens is microcolony detection 
on solid medium (49). Thinly poured plates of 
Middlebrook 7Hll agar plates are inoculated and 
examined microscopically. Detection of mycobac- 
teria using the microcolony method required about 
half the time needed for conventional culture on solid 
medium, but recovery of mycobacteria was less 
efficient than using conventional slants. This method 
is cheap but labour intensive. 
IdentiJication after culture 
Conventional identification methods include deter- 
mination of the rate of growth, growth at different 
temperatures, colony morphology, pigment produc- 
tion and susceptibility to anti-tuberculous reagents 
(e.g. p-nitrobenzoic acid, thiacetazone) (50). Using 
conventional methods, identification of the species to 
which the cultured mycobacterial strain belongs may 
require an additional 24 weeks. 
A new approach to the identification of mycobac- 
teria is the use of nucleic acid probes that hybridize 
specifically with mycobacterial RNA and DNA 
(51,52). Commercial non-radioactive DNA, probes 
complementary to ribosomal RNA (rRNA) are 
available for the M tuberculosis complex, MA1 
complex, M gordonae and M. kansasii (AccuProbe; 
Gen-Probe, San Diego, CA, U.S.A.). The probes, 
which are specific, are labelled with an acridinium 
ester and hybridization with ribosomal RNA is 
detected by chemiluminescence using a luminometer 
(53-55). 
Another method for differentiating mycobacteria is 
the identification of mycobacterial antigens in early 
cultures using polyclonal (56) or monoclonal anti- 
bodies (l&57-59) in ELISA. For the AL tuberculosis 
complex, sensitivity and specificity were both 100%. 
For the M. avium-intracellulare-scrofulaceum (MAIS) 
complex, the sensitivity was 70% and the specificity 
was 100% (57). Recently, a commercial agglutination 
test for identification of M. tuberculosis, MAIS com- 
plex and M. kansasii using coloured polystyrene 
particles coated with monoclonal antibodies has been 
introduced (MycoAKT; DynaGen, Inc., Cambridge, 
MA, U.S.A.). It is a simple and cheap test. Results 
can be obtained in approximately 1.5 h. 
Analysis of the lipid composition of mycobac- 
teria by various chromatographic procedures (gas 
chromatography, thin layer chromatography, high 
performance liquid chromatography) is recognized 
as a useful tool for differentiating mycobacterial 
species (60-63). However, these techniques require 
considerable expertise. 
Nucleic acid amplljication 
Nucleic acid (DNA or RNA) amplification tech- 
niques can detect and identify mycobacteria directly 
in clinical samples. The most extensively studied 
nucleic acid amplification technique is the polym- 
erase chain reaction (PCR) (64-66). With this 
technique, target DNA sequences are exponentially 
replicated in repeated cycles of DNA synthesis driven 
by specific oligonucleotide primers. The amplified 
DNA is usually detected by agarose gel electro- 
phoresis or by hybridization with labelled nucleic 
acid probes. Many PCR assays for the detection of 
M tuberculosis complex bacteria in clinical samples 
have been described. The most common target for 
amplification is the insertion sequence IS6110 which 
is only present in mycobacteria belonging to the 
M. tuberculosis complex (67-73). 
Polymerase chain reaction results, like microscopy, 
can be obtained within 24 h of receipt of the sample. 
The sensitivity and specificity far exceeds that of 
microscopy. Several studies have reported sensi- 
tivities ranging between 74-91% and specificities 
ranging between 95-100% when a culture of 1M. 
tuberculosis was used as the gold standard (74-77). 
To test the reliability and reproducibility of the 
PCR method for the detection of M tuberculosis in 
clinical samples, seven laboratories participated in a 
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blinded study of 200 sputa, saliva and water samples 
containing a known number of M. bovis BCG bac- 
teria or no added organisms. The insertion sequence 
IS6110 was the target for DNA amplification. Each 
laboratory followed its own protocol for the treat- 
ment of the sample, DNA amplification and detec- 
tion (78,79). A considerable variation in specificity 
among the laboratories was found. Three labora- 
tories incorrectly detected mycobacterial DNA in 
20% or more of the negative control samples. The 
levels of sensitivity also ranged widely among the 
different participants. The results of the study 
showed that the implementation of an effective 
system for monitoring sensitivity is required since 
clinical samples contain DNA polymerase inhibitors. 
Furthermore, a system to prevent contamination 
with DNA fragments from previous amplification 
reactions is an absolute necessity (73). 
The most frequent cause of false-positive results 
is contamination by minute amounts of amplified 
DNA fragments (amplicons) via aerosols, spread 
by the laboratory workers during handling of the 
PCR products (72,73). These PCR products are 
particularly dangerous for contamination because of 
the high number of molecules (1012 per reaction) 
produced in the PCR. Contamination with one 
molecule is enough to obtain a false-positive PCR 
result (73). The use of uracil DNA glycosylase in 
combination with dUTP instead of dTTP is an 
efficient way to prevent amplicon contamination 
(SO). Following 3 yr of experience with this system, 
amplicon contamination is no longer a problem to 
the author. Other methods for prevention of ampli- 
con contamination are based on photochemical 
inactivation (8 1,82). 
Another major concern in PCR is false-negative 
results caused by inhibitors of the DNA polymerase. 
The addition of a small amount of AK tuberculosis 
DNA has become common practice to control for 
this (72-75). However, this method considerably 
increases the number of PCR assays necessary for 
each clinical sample. Recently, the construction of an 
M smegmatis strain, containing a modified IS6110 
fragment integrated in the genome has been 
described. This modified M. smegmatis strain is able 
to serve as an effective internal control to monitor the 
efficacy of DNA extraction and to detect the presence 
of inhibitors of the PCR. Furthermore, the modified 
DNA target can be used for a semi-quantitative PCR 
for A4. tuberculosis (83). 
Besides stringent precautions to prevent contami- 
nation by amplicons or genomic DNA and control 
for inhibition, quality control of the PCR reaction 
mixtures and monitoring the performance of the 
amplification itself is mandatory if PCR is used for 
diagnostic purposes (73). 
Many researchers are working on a PCR assay 
detecting not only M. tuberculosis but also several 
species of mycobacteria other than M tuberculosis 
(opportunistic mycobacteria). Most of these PCR 
assays are based on 16s rRNA sequences. The 
species can be identified by restriction enzyme analy- 
sis (84,85), hybridization with species specific probes 
(86) or determination of the nucleic acid sequence of 
the PCR fragment (87). So far these assays have only 
been used for isolated mycobacterial strains. It would 
be an enormous improvement if these PCR-based 
assays for detection and identification of opportun- 
istic mycobacteria could be performed directly on 
clinical samples. 
Recently, a commercial PCR amplification kit for 
the detection and identification of M. tuberculosis 
complex bacteria has become available (Amplicor; 
F. Hoffman-La Roche, Basel, Switzerland). The 
target for the PCR is the 16s rRNA sequence. The 
detection system is based on hybridization with a 
M. tuberculosis complex-specific capture probe in a 
microplate format. Probes for the identification of 
other mycobacteria are not yet available. 
A new method based on transcription-mediated 
RNA amplification named nucleic acid sequence 
based amplification (NASBA) has been described 
(88). A NASBA assay based on 16s rRNA sequences 
for detection and identification of several myco- 
bacteria (44. leprae, M. tuberculosis, M. avium, 
M. intracellulave, M. smegmatis) has been developed 
by van der Vliet et al. (89). They showed that the 
NASBA assay can be used for the assessment of 
mycobacterial viability (90). The technique may 
be suitable for following patients during anti- 
tuberculous therapy. 
Another commercial test called Amplified 
Mycobacterium tuberculosis Direct Test (AMTDT) 
from Gen-Probe is also based on transcription 
mediated RNA amplification. Compared with the 
results of culture, the sensitivity of the Gen-Probe 
AMTDT assay ranges between 71-97% and 
specificity ranges between 96-99% (91-93). When 
compared with clinical diagnosis sensitivities of 
culture, AMTDT and PCR were respectively 91 and 
92% (94). 
The current commercially available amplification 
tests are expensive and do not control for inhibitors 
of the amplification. This may produce false-negative 
results. The great advantage of nucleic acid amplifi- 
cation reactions over culture is the speed with which 
the diagnosis can be made. Unlike microscopy, the 
infecting mycobacterium can be directly identified. 
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INDIRECT TESTS 
Antibody detection 
The detection of antibodies against mycobacterial 
antigens in sera from patients in ELISA has shown 
promising results. One of the problems of antibody 
detection tests using crude mycobacterial prepar- 
ations is the low specificity. False-positive results are 
probably due to cross-reactions induced by environ- 
mental mycobacteria and other bacteria (95,96). 
Purified antigens can be obtained from mycobacterial 
cultures using preparation techniques such as ion- 
exchange chromatography, gel filtration, iso-electric 
focusing, electrophoresis and affinity chromatogra- 
phy (977100) or from Escherichia coli clones express- 
ing mycobacterial antigens (101). The use of purified 
antigens has improved the specificity of the antibody 
detection assays (102). However, the reproducibility 
of the quality of antigens purified with these cumber- 
some techniques is variable. This makes interpret- 
ation of the data from different laboratories difficult. 
The most promising purified antigen in a number 
of ELISAs is the 38 kDa antigen from M tubercu- 
losis (102-105). The 10 kDa, 16 kDa and 24 kDa 
proteins isolated from M. tuberculosis were useful in 
ELISA, but the 30 kDa protein and the recombinant 
38 kDa and 70 kDa proteins were not (106). 
The need for purified antigens can be circumvented 
by measuring the antibody responses to specific 
epitopes by competitive inhibition of antigen binding 
by monoclonal antibodies. A competition ELISA 
using monoclonal antibody TB72 against the 38 kDa 
protein gave promising results (107-109). With a 
specificity of 97.6%, the test gave positive results in 
85% of cases of smear-positive and 70% of cases of 
smear-negative pulmonary disease and in 70-80% 
of cases of extrapulmonary tuberculosis (107). Lower 
sensitivities and specificities were reported by Verbon 
et al. using the same monoclonal antibody and sera 
from patients from different races (106). 
Instead of purified antigens or monoclonal anti- 
bodies, peptides can be used in antibody detection 
assays. Using overlapping peptides of 20 amino 
acids, several epitopes recognized by different anti- 
bodies have been identified, e.g. those on the 10 kDa 
and 16 kDa proteins of M tuberculosis (110,111). 
Sera from patients which recognized the purified 
10 kDa and 16 kDa proteins, failed to recognize 
the synthetic peptides. Apparently the majority of the 
antibodies against these antigens in humans are 
directed against conformational epitopes (110,111). 
The humoral response in mycobacterial disease 
seems to be associated with HLA class II allotypes 
(112). Different patients seem to recognize different 
antigens (96, 102). These findings suggest that it is 
unlikely that a single antigen will be recognized by all 
patients with tuberculosis. When selecting antigens 
for antibody detection assays, serum from patients 
from different racial origins (and thus different HLA 
class II allotypes) should be used. The combination 
of ELISA results obtained with a set of species- 
specific and immunodominant antigens may result in 
a test with optimal sensitivity and specificity (106). 
Unfortunately, the sensitivity of tests based on detec- 
tion of IgG antibodies drops dramatically in tuber- 
culosis patients with HIV due to their impaired 
humoral immunity (106,113). 
Skin tests 
Assessment of the patient’s delayed type hyper- 
sensitivity (DTH) reaction following an intracu- 
taneous injection of a pre-determined amount of 
tuberculin or purified protein derivative (PPD) 
remains the simplest, most accurate and most fre- 
quently used method of inferring tuberculosis 
infection (114). This skin test does not discriminate 
between active tuberculosis, past infection with 
mycobacteria or BCG vaccination. The skin test can 
be helpful in areas with a low prevalence of tubercu- 
losis where BCG vaccination is not routinely given. 
False-negative tests occur and may be due to anergy. 
Research aimed at developing a more specific skin 
test has focused on the use of purified antigens. A 
M. tuberculosis antigen with a molecular weight of 
38 kDa elicited a positive skin reaction in BCG 
vaccinated guinea pigs. The antigen appeared to be 
more specific than PPD and was the most potent 
elicitor of a tuberculin-like skin reaction (115). 
Vordermeier et al. reported an immunodominant 
T-cell-stimulatory epitope (38.G), located near the 
carboxy-terminus of the 38 kDa antigen from AK 
tuberculosis. Peptide 38.G elicited DTH and stimu- 
lated the proliferation of peripheral blood lympho- 
cytes from healthy, PPD-positive individuals but not 
from PPD-negative individuals. This peptide could 
be useful for new molecularly defined skin test 
reagents (116). 
Several other proteins or peptides from M 
tuberculosis or M. bovis BCG have been reported to 
induce DTH reactions in animal models, for instance 
the 10 kDa protein (117), the 18 kDa protein (99) 
and the 24 kDa protein (118). 
A promising new field of research in DTH tests 
is the definition of antigens that can discriminate 
between vaccination and recent infection. The 
24 kDa antigen from M bovis BCG has been used in 
a DTH test to differentiate between BCG immunized 
and M. tuberculosis-infected guinea pigs (118). 
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It should be noted that tests based on humoral and 
cellular immune response towards mycobacterial 
infection have limited value in a population with a 
high incidence of HIV seropositivity. 
How Should the Tests he Used? 
Today the hallmarks of diagnosis are still the 
detection of acid-fast bacteria by direct microscopy 
and identification of cultured mycobacteria by bio- 
chemical tests. Microscopy is the easiest and quickest 
diagnostic procedure than can be performed, but has 
limited sensitivity (> lo4 bacteria ml - ‘) and cannot 
identify the mycobacterial species. The currently rec- 
ommended culture procedure involves the use of two 
solid media and one liquid medium (37). Culture of 
mycobacteria is time-consuming, requiring a mean 
time of 4 weeks of incubation when using conven- 
tional media before growth is detected. Using the 
Bactec radiometric system, the time for culture can be 
reduced to 2 weeks. The speed of the test makes this 
test suitable for drug sensitivity testing. 
Culture to identify the organism is important 
in situations where mycobacteria other than M. 
tuberculosis could be the cause of disease. Even in 
countries with a high incidence of tuberculosis and 
HIV infection, A4. tuberculosis remains the most 
common infecting mycobacterium (17,18). Antibody 
and antigen detection assays have yet to prove their 
worth in daily practice. 
Modified microscopy with centrifugation of 
the clinical sample is an effective improvement in the 
diagnosis of tuberculosis. A test that combines the 
rapidity of microscopy and the sensitivity of culture 
would be of great help to the clinician during the 
initial management of the patient. DNA and RNA 
amplification techniques will be increasingly used for 
the diagnosis of tuberculosis. They have a much 
higher sensitivity than microscopy and results are 
available within 24 h. An additional advantage is the 
direct identification of the organism as belonging to 
the M. tuberculosis complex. 
Nucleic acid amplification techniques are unnecess- 
ary when reliance can be placed on the interpretation 
of a positive microscopy result, when this is in 
accordance with the clinical findings. Amplification 
techniques should be performed when microscopy is 
positive but there is a chance that infection is due to 
mycobacteria other than M tuberculosis or when 
microscopy reveals very few or no acid-fast bacteria. 
Clinical samples for which nucleic acid amplification 
tests for M. tuberculosis give a positive result still 
have to be inoculated on culture media when drug 
sensitivity testing is required. In the near future, 
nucleic acid amplification based tests will be available 
for the detection and identification directly in clinical 
samples of A4 tuberculosis and mycobacteria other 
than hf. tuberculosis (Kox et al., in preparation). 
Moreover, simple PCR-based assays for detection of 
rifampicin resistant M. tuberculosis (120,121) directly 
in clinical samples will become available. When direct 
tests for determining drug resistance of mycobacteria 
to the other anti-mycobacterial drugs are available, 
the need for culture of mycobacteria from clinical 
samples will further decrease. 
In most laboratories in Europe, more than 90% of 
the samples sent for testing are negative for myco- 
bacteria. Nucleic acid amplification gives the best 
chance of detecting mycobacteria in the ‘less than 
10% positive’ samples. These samples alone could 
then be cultured for drug sensitivity testing. Ideally, 
nucleic acid amplification techniques in this situation 
should be applicable to all sorts of clinical samples 
and should include specific probes to differentiate 
between M tuberculosis and other mycobacteria. 
Another option could be to culture all samples 
and only select those microscopy-negative samples 
from patients in whom there is a high index of 
suspicion of mycobacterial infection for nucleic acid 
amplification. 
Given current cost constraints in the health system, 
it is unlikely that most laboratories will be able to do 
both nucleic acid amplification and culture routinely 
on all samples. Each diagnostic centre must evaluate 
for its own population and economic situation, the 
cost-effectiveness and cost benefits of the available 
diagnostic techniques. 
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